Skip to main content
. 2023 May 26;25(6):687–694. doi: 10.4103/aja202316

Figure 4.

Figure 4

ENZ combined with OLA inhibits NHEJ and induces apoptosis. (a) Heatmap of the expression levels of some NHEJ genes following indicated treatment. (b) The mRNA expression level of PRKDC and XRCC4 in C4-2 and LNCaP cells with indicated treatments. (c) The expression of DNA-PKcs and XRCC4 in C4-2 and LNCaP after indicated treatments monitored by Western blot. (d) The expression of DNA-PKcs and γH2AX after the knockdown of DNA-PKcs monitored by Western blot. (e) Expression of PRKDC in TCGA database according to Gleason score. (f) PRKDC expression of tumor and normal tissues in TCGA database. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (ANOVA). ENZ: enzalutamide; OLA: olaparib; NHEJ: nonhomologous end joining; PRKDC: protein kinase DNA-activated catalytic subunit; XRCC4: X-ray repair cross complementing 4; DNA-PKcs: DNA-dependent protein kinase catalytic subunit; γH2AX: gamma H2A histone family member X; si: small interfering; TCGA: The Cancer Genome Atlas; GS: Gleason score; TPM: transcripts per million; PRAD: prostate adenocarcinoma; T: tumor; N: normal; ANOVA: analysis of variance; NC: normal control.